Ramucirumab specifically binds to VEGFR2, inhibiting angiogenesis, and is primarily employed to treat gastric cancer,178 colorectal cancer,179 lung cancer,180 and hepatocellular carcinoma.181. Here, KDR is linked to hepatocellular carcinoma.